Helicobacter pylori is a human pathogen that colonizes about 50% of the world's population, causing chronic gastritis, duodenal ulcers and even gastric cancer. A steady emergence of multiple antibiotic resistant strains poses an important public health threat and there is an urgent requirement for alternative therapeutics. The blood group antigen-binding adhesin BabA mediates the intimate attachment to the host mucosa and forms a major candidate for novel vaccine and drug development. Here, the recombinant expression and crystallization of a soluble BabA truncation (BabA 25-460 ) corresponding to the predicted extracellular adhesin domain of the protein are reported. X-ray diffraction data for nanobody-stabilized BabA 25-460 were collected to 2.25 Å resolution from a crystal that belonged to space group P2 1 , with unit-cell parameters a = 50.96, b = 131.41, c = 123.40 Å , = 90.0, = 94.8, = 90.0 , and which was predicted to contain two BabA 25-460 -nanobody complexes per asymmetric unit.
Introduction
Helicobacter pylori is a Gram-negative bacterium that colonizes the gastric mucosa of about 50% of the world's population. Unless treated with antibiotics, H. pylori infections are usually persistent and are associated with chronic gastric inflammation, which in symptomatic carriers can develop into gastric and duodenal ulcers and even gastric malignancies such as mucosa-associated lymphoid tissue (MALT) lymphoma and gastric adenocarcinoma (Every, 2013) .
H. pylori infection is dependent on a complex interplay between the bacterium and its human host. Apart from environmental factors and host genetic predisposition, a number of H. pylori virulence factors are associated with more severe clinical outcomes of infection (Delahay & Rugge, 2012; Backert & Clyne, 2011) . Along with the secreted virulence factors CagA and VacA, another important virulence trait of H. pylori is the ability to strongly adhere to the gastric mucosa. The blood group antigen-binding adhesin (BabA) is a major adhesin that interacts with fucosylated Lewis b (Le b ) and H type 1 blood group antigens on the surface of human gastric epithelial cells (Boré n et al., 1993; Aspholm-Hurtig et al., 2004; Moore et al., 2011) . The reference strain CCUG17875 possesses two babA genes: a silent babA1 locus and a babA2 gene that is expressed as functional BabA adhesin (Ilver et al., 1998) . In conjunction with the cagA and vacA s1 alleles, a babA2-positive genotype is found to be associated with duodenal ulcer disease and gastric cancer (Gerhard et al., 1999) .
In recent years, multidrug-resistant H. pylori strains have spread worldwide, creating a demand for new therapeutics that can both treat and prevent infections. In Gram-negative bacteria, secretion pathways play an important role in pathogenesis and recent studies have focused on chemotherapeutics for the directed intervention in secretion machineries such as bacterial pili that mediate host-cell adhesion (Lo et al., 2013) .
Hence, in a quest for the rational design of structure-based antiadhesives, we initiated structural characterization of the BabA-Le b interaction. BabA is one of the members of the Helicobacter outer membrane porin (HOP) family. Comparative genome analysis and predicted secondary-structure analysis of HOP adhesins highlight a conserved C-terminal domain predicted to be the corresponding membrane-anchoring -barrel domain, which is preceded by a variable domain that is expected to contain the adhesive properties (Tomb et al., 1997; Alm et al., 2000) . This architecture is reminiscent of autotransporter-like proteins, in which a C-terminal -barrel guides the secretion of an N-terminally located passenger domain. Here, we report the expression and purification of a BabA truncation corresponding to the putative N-terminal adhesin domain and show that an N-terminal construct spanning amino-acid residues 25-460 can be expressed as a stable folded unit. We further report on the crystallization of the N-terminal soluble adhesin domain with the aid of nanobodies, which are camelid-derived single-domain antibodies that have successfully been used as crystallization chaperones, for example in the case of conformationally complex or aggregating proteins (Steyaert & Kobilka, 2011; Baranova et al., 2013) .
Materials and methods
2.1. Cloning, expression and purification of BabA truncations DNA coding sequences corresponding to the BabA fragments BabA 1-460 , BabA 1-480 , BabA 1-496 , BabA 1-523 and BabA 1-546 were PCR-amplified from H. pylori CCUG 17875 genomic DNA using primers (the forward primer BabA_IbaHR4-f and the reverse primers BabA_IbaHR4_460-r, BabA_IbaHR4_480-r, BabA_I-baHR4_523-r and BabA_IbaHR4_546-r) shown in Table 1 . The amplicons were digested with BsaI and cloned into pASK-HR4, a derivative of the pASK-IBA32 vector (IBA GmbH) with the Nterminal ompA leader sequence replaced by the dsbA leader. DNA fragments corresponding to BabA 25-460 , BabA 25-480 , BabA 25-523 and BabA 25-546 were PCR-amplified from their respective pASK-HR4 parent constructs using primers (forward primer BabA_IbaHR3-f and reverse primer BabA_IbaHR3-r) as provided in Table 1 , digested with BsaI and cloned into pASK-HR3, a pASK-IBA12-derived vector in which the ompA leader sequence was replaced by the dsbA leader. Thus, the resulting BabA fragments comprise an N-terminal DsbA signal peptide for periplasmic expression followed by a thrombin-cleavable Strep-tag II and a 6ÂHis tag at their C-terminal end. Escherichia coli TOP10 cells were transformed with the pASK-HR3 or pASK-HR4 constructs, grown on lysogeny broth (LB) supplemented with 100 mg ml À1 ampicillin until an OD 600 of 0.7 was reached and induced overnight at 293 K with 0.2 mg ml À1 anhydrotetracycline.
For large-scale expression for functional and structural analysis, TOP10 cells grown and induced as described above were harvested by centrifugation at 6238g for 15 min at 277 K using a JA-8.1 rotor in an Avanti-J26 XP Beckman Centrifuge. Periplasmic extraction was performed by suspending the cells in 4 ml 20 mM Tris-HCl pH 8.8, 20%(w/v) sucrose (per 1 g of wet cell pellet) with the protease inhibitors AEBSF-HCl (0.4 mM) and leupeptin (1 mg ml À1 ) followed by treatment with 40 ml 0.5 M EDTA and 40 ml lysozyme (10 mg ml À1 ) and mixing gently on ice for 20 min. 80 ml 1 M MgCl 2 was added and the periplasmic extract was cleared from spheroplasts by centrifugation at 17 418g for 20 min at 277 K in a JA-20 rotor. The periplasmic extract was further clarified by centrifugation at 48 384g for 30 min at 277 K in the same rotor and filtered through a 0.45 mm syringe filter.
BabA fragments were purified by consecutive nickel and Strep-Tactin affinity chromatography. Briefly, the periplasmic extract was loaded onto a 5 ml pre-packed Ni-NTA column (GE Healthcare) pre-equilibrated with buffer A (20 mM Tris-HCl pH 8.8, 250 mM NaCl, 5% glycerol), washed with five bed volumes of buffer A and the bound protein was eluted with 280 mM imidazole in buffer A. Eluted peak fractions were collected and loaded onto a 5 ml pre-packed Strep-Tactin column (IBA GmbH) equilibrated with buffer C (20 mM Tris-HCl pH 8.8, 150 mM NaCl, 5% glycerol), washed with five bed volumes of buffer C and the bound protein was eluted with 0.6 mg ml À1 d-desthiobiotin in buffer C. In addition to the crystallization trials for these BabA truncations, we opted for a nanobodyaided crystallization approach. For this purpose, we used Nb-ER19, a nanobody raised against native full-length BabA purified from the outer membrane of H. pylori strain CCUG 17875. Nb-ER19 was produced and purified as described elsewhere (Baranova et al., 2013; Pardon et al., 2014) .
To form BabA-Nb-ER19 complexes, the periplasmic extracts of the BabA truncations (BabA 25-460 , BabA 25-523 and BabA 25-546 ) and Nb-ER19 were mixed in a 5:1(v:v) ratio on ice and nickel-affinity purification was performed as described above. Fractions containing the respective BabA fragments and Nb-ER19 were pooled and concentrated in a 10 kDa molecular-weight cutoff spin concentrator to a final volume of 500 ml. The concentrated sample was then loaded onto a Superdex S-200 16/60 column (GE Healthcare) pre-equilibrated with 20 mM sodium acetate pH 5.0, 150 mM NaCl, 5% glycerol. Eluted fractions containing the BabA-Nb-ER19 complex, with the affinity purification tags intact, were pooled and concentrated to a final concentration of 15 mg ml À1 using a 10 kDa molecular-weight cutoff spin concentrator prior to crystallization.
Crystallization
Crystallization of BabA 1-460 , BabA 25-460 and its complex with Nb-ER19 was first screened at 293 K by the sitting-drop vapour-diffusion method with commercial sparse-matrix crystallization screening kits protein solution and 400 nl reservoir solution (a 1:1 ratio) and equilibrating against 50 ml reservoir solution. Crystallization information is summarized in Table 2 .
Data collection and processing
A BabA 25-460 -Nb-ER19 crystal grown in 0.2 M sodium nitrate, 0.1 M bis-tris propane pH 6.5, 20%(w/v) PEG 3350 and supplemented with 10% glycerol was mounted in a SPINE-standard nylon loop and flash-cooled in liquid nitrogen. Diffraction data for the native protein were collected on beamline I04 at Diamond Light Source, Didcot, England equipped with a PILATUS 6M CCD detector. The diffraction data were processed with XDS and xia2 (Kabsch, 2010) and truncated to 2.25 Å resolution on the basis of an I/(I) cutoff of 2. The crystals belonged to the monoclinic space group P2 1 , with unit-cell parameters a = 50.960, b = 131.410, c = 123.40 Å , = 90.00, = 94.80, = 90.00 , compatible with two to three BabA 25-460 -Nb-ER19 complexes per asymmetric unit, corresponding to a calculated V M of 3.3 and 2.2 Å 3 Da À1 and a solvent content of 60 and 41%, respectively (Matthews, 1968) . Crystallographic data statistics are presented in Table 3 .
Results and discussion
On the basis of comparative genome analysis and secondary-structure prediction of HOP adhesins, we made C-terminal truncation constructs that remove the predicted -barrel domain. In this way, five constructs were generated with truncation sites falling inbetween predicted secondary-structure elements upstream of the Cterminal -strand region: BabA 1-460 , BabA 1-480 , BabA 1-496 , BabA 1-523 and BabA 1-546 . Although these constructs were found to result in the expression of recombinant protein of the expected molecular weight, the expression products were mostly found in the insoluble fraction and the protein fractions purified from the periplasmic extracts were found to be prone to aggregation. Mass-spectrometric analysis showed the rapid proteolytic loss of the first 23 N-terminal residues (Fig. 1a ), indicating these were not part of a stably folded core in the BabA truncates. Based on this susceptibility to degradation, we modified the babA 1-460 , babA 1-480 , babA 1-523 and babA 1-546 constructs to remove the first 24 amino acids of the mature protein.
With the exception of BabA 25-480 , the remaining N-terminal deletion constructs resulted in the periplasmic expression of soluble recombinant BabA fragments corresponding to the expected molecular weight (Fig. 1b) . On analytical size exclusion (Superdex 75 10/300; Fig. 2a ), the minimal fragment, BabA 25-460 , eluted as a single peak corresponding to a calculated molecular mass of about 52 kDa, matching that expected for a BabA 25-460 monomer with N-terminal and C-terminal tags (49 319 Da). When analysed by circular-dichroism (CD) spectroscopy, the BabA 25-460 truncation showed a folded conformation with a high -helical secondary-structure content (Fig. 2b) . A dominant -helical secondary structure was also observed in the recently solved structure of the H. pylori HOP adhesin SabA (Pang et al., 2014) . Similar to BabA 25-460 , expression of BabA 25-523 and BabA 25-546 resulted in folded recombinant BabA fragments (data not shown).
Recombinant proteins were concentrated to 10-15 mg ml À1 and subjected to crystallization trials using the commercially available sparse-matrix screens described above. Extensive screens for the BabA fragments did not result in the growth of single crystals in the conditions used. Hence, we opted for a nanobody-aided crystallization approach. Crystals of BabA 25-460 -Nb-ER19 were obtained in multiple different conditions of the PACT premier and JCSG-plus screens after 1-2 d incubation at 293 K. Optimization of PACT premier screen condition F5 with differing PEG 4000 concentrations (16-24%) also led to the reproducible growth of cube-shaped crystals of average dimensions of 0.06 Â 0.06 Â 0.06 mm (Fig. 3a) . SDS-PAGE analysis of washed and dissolved crystals confirmed that these contained both BabA 25-460 and Nb-ER19 (Fig. 3a, inset) .
A crystal grown in 0.2 M sodium nitrate, 0.1 M bis-tris propane pH 6.5, 20%(w/v) PEG 3350 diffracted to at least 2.25 Å resolution (Fig.  3b ). The crystal belonged to the monoclinic space group P2 1 , with unit-cell parameters compatible with a predicted two or three BabA 25-460 -Nb-ER19 complexes per asymmetric unit. Selenomethionine-derivatized protein is in production to allow experimental phase determination by a single anomalous dispersion experiment. The high-resolution structure of the BabA extracellular domain will be invaluable in understanding its ligand-binding properties and is anticipated to facilitate the development of anti-adhesive compounds that may serve as novel therapeutic and/or prophylactic eradication therapies against H. pylori.
